(Zymergen says in the prospectus: “In connection with our initial public offering, we plan to convert to a public benefit corporation incorporated in Delaware as a demonstration of our long-term commitment to our mission to displace the petrochemicals that pollute the Planet by designing, developing, and commercializing bio-based materials that deliver better performance than existing products, at attractive costs.”)

We partner with Nature to design, develop, and commercialize bio-based breakthrough products that deliver extraordinary value to customers in a broad range of industries. Our first innovations include films designed for electronics companies to use in new categories of smart devices, including rollable tablets and naturally derived UV protection. Our consumer products include ZYM0201, a naturally derived non-DEET insect repellent, and we plan on partnering to create a microbial alternative to synthetic nitrogen fertilizer. We call our process biofacturing and we expect it will create better products faster, cheaper and more sustainably than traditional chemistry by engineering microbes to make novel biomolecules that are the key ingredients in those products. Our goal is to launch our products in about half the time and 1/10^th of the cost (about five years and $50 million per product) of what traditional chemicals and materials companies can deliver, which would allow us to address a wide array of commercial applications.

(Note: Zymergen, Inc. upsized its IPO at pricing on April 21, 2021, to 16.3 million shares, up from 13.6 million in the prospectus,  at $31 – the top of its $28-to-$31 price range – to raise $505.3 million.)